Rheumatic manifestations of renal disease

Current Opinion in Rheumatology

Volumn 21, Issue 1, 2009, Pages 55-61

  Bardin, Thomas ^a   Richette, Pascal ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Adynamic bone disease; Chronic kidney disease (CKD); Gadolinium; Haemodialysis; Hyperphosphatemia; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Renal osteodystrophy; Secondary hyperparathyrodism; Vascular calcification

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; FALECALCITRIOL; GADODIAMIDE; GADOLINIUM; IMATINIB; MAXICALCITOL; PARACALCITOL; PARATHYROID HORMONE; PENTOXIFYLLINE; PHOSPHATE; PHOSPHATE BINDING AGENT; SODIUM THIOSULFATE; TRANSCRIPTION FACTOR OSTERIX; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ASSAY; ATTENTION; BLOOD VESSEL CALCIFICATION; BONE; BONE DISEASE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DEATH; EXPERIMENTAL STUDY; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; IATROGENIC DISEASE; MODULATION; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SECONDARY HYPERPARATHYROIDISM; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

CALCINOSIS; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; GADOLINIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; NEPHROGENIC FIBROSING DERMOPATHY; RENAL OSTEODYSTROPHY; RHEUMATIC DISEASES;

EID: 58149215918     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32831ca5c5     Document Type: Review

References (70)

1. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQl-recommended intact PTH • levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73:771 -777. This histologic study in one dialysis center shows that implementation of the K/DOQl recommendation on PTH levels did not prevent ABD.
2. Ferreira A, Frazao JM, Monier-Faugere MC, et al Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19:405-412.
3. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41 :I-IV, S1-S91.
4. Martin KJ, Gonzalez EA. Parathyroid hormone assay: problems and oppor- •• tunities. Pediatr Nephrol 2007; 22:1651-1654. The lack of accuracy of presently available PTH assays and the limitation caused to the management of ROD are reviewed.
5. Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753-761.
6. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70:345-350.
7. Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol 2003; 15:48-54.
8. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208- 2218.
9. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942.
10. Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a •• cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19:1092 -1105. This in-vitro study explores the mechanism of vascular calcification and demonstrates that hyperphosphatemia has an active role, by inducing osterix, in addition to contributing to a high Ca x P product.
11. Mendoza FJ, Lopez I, Montes de Oca A, et al. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008; 73:407-414.
12. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74:148-157.
13. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199:271 -277.
14. London GM, Marchais SJ, Guerin AP, et al. Association of bone activity, •• calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19:1827-1835. This important study shows that the amount of aortic calcification associated with oral calcium load is a function of bone turnover and is increased when bone turnover is decreased.
15. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22:860-866.
16. Mathew S, Lund RJ, Chaudhary LR, et al Vitamin D receptor activators can • protect against vascular calcification. J Am Soc Nephrol 2008; 19:1509- 1519. The effect of vitamin D receptor activators on vascular calcification depends on their dosage. Low doses can be protective by inhibiting PTH secretion.
17. Levin A, Bakris GL, Molitch M, et al Prevalence of abnormal serum vitamin D, • PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31 -38. This study of CKD patients before dialysis gives reliable estimates of mineral metabolism parameters in a large unreferred population.
18. Gutierrez OM, Isakova T, Andress DL, et el. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008; 73:956-962.
19. Andress DL, Coyne DW, Kalantar-Zadeh K, et al Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract 2008; 14:18-27.
20. Gutierrez O, Isakova T, Rhee E, et al Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
21. Stavroulopoulos A, Porter CJ, Roe SD, et al Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton) 2008; 13:63-67.
22. Isakova T, Gutierrez O, Shah A, et al Postprandial mineral metabolism and •• secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19: 615-623. This new study of postprandial mineral metabolism in CKD stage 3-4 patients and healthy volunteers did not show postprandial changes in FGF 23 or phosphorus, but an inadequate increase of calciuria in CKD patients which led to transient and slight hypocalcemia and increased PTH.
23. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al Survival predictability of timevarying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771 -780.
24. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary • hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73:1296-1302. In CKD patients not treated with dialysis the same association as in dialysis patients of severe HTP with increased mortality was observed.
25. Baber U, de Lemos JA, Khera A, et al Nontraditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 2008; 73:615-621.
26. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168:397-403.
27. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008; 12:55-61.
28. Suki WN, Zabaneh R, Cangiano JL, et al Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72:1130-1137.
29. Asmus HG, Braun J, Krause R, et al Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20:1653-1661.
30. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-252.
31. Palmer SC, McGregor DO, Macaskill P, et al Meta-analysis: vitamin D •• compounds in chronic kidney disease. Ann Intern Med 2007; 147:840- 853. This very carefully done metaanalysis shows that the largely used vitamin D compounds are prescribed on fragile grounds and call for more trials based on patient-level outcomes.
32. Wolf M, Shah A, Gutierrez O, et al Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004-1013.
33. Al-Aly Z. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials. Kidney Int 2007; 72:909-911.
34. Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2007; 147:880-881.
35. Block GA, Martin KJ, de Francisco AL, et al Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525.
36. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid •• hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007; 22:1828-1839. A nice review on the effect of calcimimetics on parthyroid gland.
37. Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007; 37:915-922.
38. Malluche HH, Monier-Faugere MC, Wang G, et al An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69:269-278.
39. Block GA, Zeig S, Sugihara J, et al Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23:2311 -2318.
40. Messa P, Macario F, Yaqoob M, et al The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3:36-45.
41. Jean G, Chazot C, Charra B. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol Dial Transplant 2007; 22:2102-2103.
42. Spasovski G, Vanholder R. Effect of lowering dialysate calcium on bone and •• mineral parameters related to adynamic bone disease. Ther Apher Dial 2007; 11:455-456; author reply 457. This study suggests that using dialysates with a low-calcium concentration could improve dialysis patients with a dynamic bone disease by stimulating PTH secretion.
43. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66:191 -199.
44. Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of reninangiotensin system involvement. J Am Acad Dermatol 2008; 58:1025- 1030.
45. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108.
46. Singh M, Davenport A, Clatworthy I, et al A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 2008; 158:1358-1362.
47. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158:273- 280.
48. Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008; 59:218-224.
49. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 968-975.
50. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008; 190:1060-1068.
51. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 2008; 17:315-319.
52. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic • systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433-3441. This interesting study of a cohort of haemodialysis patients implies gadopentate dimeglumine as a cause of NSF and shows that NSF is associated with increased short-term mortality.
53. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157.
54. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7:2425-2432.
55. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66:175-179.
56. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent •• 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214:584-593. This experimental study brings evidence that gadoliamide is a cause of NSF.
57. Sieber MA, Lengsfeld P, Frenzel T, et al Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18:2164-2173.
58. Lu CF, Hsiao CH, Tjiu JW. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor. J Eur Acad Dermatol Venereol 2008 [Epub ahead of print].
59. Rydahl C, Thomson HS, Marckmann P. High prevalence of nephrogenic • • systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-144. An interesting study that documents the risk of NSF as a function of renal impairment and gadolinium exposure.
60. Swaminathan S, High WA, Ranville J, et al Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73:1413-1418.
61. Saussereau E, Lacroix C, Cattaneo A, et al. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 2008; 176:54-57.
62. Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008; 190:1069- 1075.
63. Swaminathan S, Horn TD, Pellowski D, et al Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 357:720-722.
64. Kallen AJ, Jhung MA, Cheng S, et al Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a casecontrol study. Am J Kidney Dis 2008; 51:966-975.
65. Marckmann P, Skov L, Rossen K, et al Case-control study of gadodiamiderelated nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22:3174-3178.
66. Kay J, Bazari H, Avery LL, Koreishi AF. Case 6-2008: a 46-year-old woman • with renal failure and stiffness of the joints and skin. N Engl J Med 2008; 358:827-838. An interesting case report with instructive discussion and literature review.
67. Khurana A, Nickel AE, Greene JF Jr, et al Successful pregnancy in a hemodialysis patient and marked resolution of her nephrogenic systemic fibrosis. Am J Kidney Dis 2008; 51 :e29-e32.
68. Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant 2008; 23:3280-3282.
69. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2:258-263.
70. Perazella MA, Reilly RF. Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. Semin Dial 2008; 21:171-173.